About Peviva
PEVIVA was established in 2000, having been granted exclusive rights to a unique apoptosis marker for keratin 18 (K18) expressing cells of epithelial origin. We strive to continuously acquire and develop novel intellectual property from the academic research and healthcare market for the detection and quantification of different forms of cell death in normal or pathophysiological circumstances.
The M30 Apoptosense® ELISA - based on the well established M30 antibody (M30-CytoDEATH™) specific for the apoptosis specific neo-epitope of K18 (K18Asp396-NE or M30 neo-epitope) - was launched in late 2000 and represents the forerunner to a novel series of immunoassays with unique specificity for different modes of cancer cell death for in vitro as well as in pre-clinical research and diagnostic applications. The M30 Apoptosense® ELISA is expected to have wide applications in clinical routine and functional evaluation of pro-apoptotic drug candidates. Due to its unrivalled sensitivity and combined with a proprietary optimised formulation it can be used with human serum or plasma samples with the prospect to assist the optimal selection and subsequent monitoring of anti-cancer therapy schedules in the future.
The M30 Apoptosense® ELISA represents the unique opportunity to use a single, standardized apoptosis detection assay for cancer cells to be employed from the initial functional drug screen extending towards a potential valuable therapy response marker in following clinical trial phases.
The M65® ELISA is intended for the quantitative detection of total caspase-cleaved and unmodified K18 released from dying cells. This product is used for assessment of all types of cell death. The combination of M65®ELISA and the M30 Apoptosense® ELISA standardized against the same reference represents a novel and unique concept of two serum markers to assess the level of total epithelial (e.g. carcinoma) cell death (quantity of K18 released from dying cells) and the relative contribution of different modes of cell death: apoptosis (through M30 Apoptosense® ELISA) and necrosis (M30 Apoptosense® ELISA / M65®ELISA ratio).
PEVIVA's Corporate Mission is to:
Invent, develop and market innovative high-quality biomarkers for use in cell-based research in academia, biotech/pharmacy industry and healthcare diagnostics and to expand the product line into related areas of research and diagnostics of different human malignancies.
Complement these markets through the development of innovative detection and screening technologies.
To support the advancement of sciences by establishing co-operations with the worldwide community of clinical research as well in partnership with other equally highly committed commercial partner companies.
PEVIVA's Quality Commitment:
We are committed to providing the highest quality service. If you would like to learn more about PEVIVA or our expanding product range, please do not hesitate to contact us.
PEVIVA's quality assurance system is certified according to SS-EN ISO 9001 and SS-EN ISO 13485.
The M30 Apoptosense® ELISA and M65®ELISA are registered with the Swedish Medical Products Agency in accordance with the regulations on medical devices and on medical devices for in vitro diagnostics respectively (CE-IVD).
Having produced and delivered thousands of M30 Apoptosense® ELISA and M65® ELISA kits over several years, the quality and reliability of PEVIVA products have been appreciated and acknowledged by third party publications.
The VAT registration number is SE556572629501.
PEVIVA AB
Voltavägen 13
SE - 168 69 Bromma
Sweden
Telephone:
+ 46 8 122 053 00
Facsimile:
+ 46 8 730 16 10
E-mail:
» info@peviva.se
Website:
» http://www.peviva.se
